Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Humacyte Inc (HUMA)

Humacyte Inc (HUMA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Humacyte Clinical Results Highlighting Benefit of the ATEVâ„¢ in the Repair of Civilian and Military Arterial Injuries Published in JAMA Surgery

HUMA : 4.53 (+2.72%)
Insider Sale: President of $HUMA (HUMA) Sells 427,459 Shares

Laura E Niklason, the President of $HUMA ($HUMA), sold 427,459 shares of the company on 11-19-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately 17.7% of their...

HUMA : 4.53 (+2.72%)
Humacyte Presents Preclinical Results of Small-Diameter ATEV™ for Coronary Artery Bypass Grafting at American Heart Association’s Scientific Sessions 2024

HUMA : 4.53 (+2.72%)
Humacyte Announces Pricing of $15.0 Million Registered Direct Offering

HUMA : 4.53 (+2.72%)
Humacyte’s (HUMA) Lab-Grown Vessels Await FDA Approval for Vascular Trauma Use

Humacyte (HUMA) is advancing the field of regenerative medicine with its lab-grown blood vessels, known as acellular tissue-engineered vessels (ATEVs), poised to transform treatment options for patients...

HUMA : 4.53 (+2.72%)
Humacyte Third Quarter 2024 Financial Results and Business Update

HUMA : 4.53 (+2.72%)
Humacyte (HUMA) Faces Key Regulatory Hurdles Ahead of Q3 Earnings

Humacyte (HUMA), a clinical-stage biotech firm developing implantable human tissue, is set to announce its third-quarter financial results on November 8, 2024. The company, known for its acellular tissue-engineered...

HUMA : 4.53 (+2.72%)
Humacyte to Present Third Quarter Financial Results and Provide Corporate Update on November 8, 2024

HUMA : 4.53 (+2.72%)
Humacyte (HUMA) Faces Regulatory Scrutiny as FDA Raises Quality Concerns

Humacyte (HUMA) experienced a decline of 1.94% in its latest trading session, closing at $5.05, which was slightly more than the S&P 500's 1.86% daily loss. Over the past month, Humacyte's shares have...

HUMA : 4.53 (+2.72%)
Insider Sale: Director at Humacyte (HUMA) Sells 1,548 Shares

Kathleen Sebelius, a director at Humacyte ($HUMA), sold 1,548 shares of the company on 09-10-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately 3.6% of their...

HUMA : 4.53 (+2.72%)

Barchart Exclusives

1 EV Stock Under $10 With 25% Upside Potential
This charging stock has been under heavy pressure lately amid concerns over the fate of EV tax credits. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar